Phio Pharma initiates Phase Ib trial of melanoma treatment

Source: Clinical Trial Arena, April 2022

Phio Pharmaceuticals has initiated subject enrolment in the Phase Ib clinical trial of its lead programme, PH-762, to treat advanced melanoma.

The trial is being carried out at the Gustave Roussy Institute, the largest cancer centre in Europe.

It will assess the safety, tolerability, pharmacokinetics and anti-tumour activity of PH-762 in participants with advanced melanoma in a neoadjuvant setting.

READ THE ORIGINAL FULL ARTICLE